Looking Into bluebird bio’s Return On Capital Employed
According to Benzinga Pro data, during Q3, bluebird bio (NASDAQ:BLUE) posted sales of $71 thousand. Earnings were up…
Analyst Ratings for bluebird bio
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings:
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording gains in the previous session.
Recap: bluebird bio Q3 Earnings
bluebird bio (NASDAQ:BLUE) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Gainers
FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.
AstraZeneca-Merck’s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October’s Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.
Short Volatility Alert: bluebird bio, Inc.
On Wednesday, shares of bluebird bio, Inc. (NASDAQ: BLUE) experienced volatile short activity. After the activity, the stock price went down -10.06% to $6.17.
The overall sentiment for BLUE has been Bearish.